“Three big U.S. pharmaceuticals announced vaccine deals of, $1.8 Billion to make the “Swine Flu Vaccine”…..Flu Pandemic or Big Business?

The US government has committed $1.8 billion to companies to make a swine flu vaccine, Reuters reported on September 30, 2009, in an article with the headline, Big pharma jumps back into flu business.

The US government "has committed $1.8 billion to companies to make a swine flu vaccine," Reuters reported on September 30, 2009, in an article with the headline, "Big pharma jumps back into flu business."

Abbott Labs bought a Belgian drug business, along with its flu vaccine facilities, for $6.6 billion. Johnson & Johnson invested $444 million in a Dutch biotech firm (Crucell) that makes and develops flu vaccines. Merck which already makes vaccines for shingles and other diseases, struck a deal to distribute flu shots made by Australian CSL, ABC News reported on October 14, 2009

"Abbott Labs bought a Belgian drug business, along with its flu vaccine facilities, for $6.6 billion. Johnson & Johnson invested $444 million in a Dutch biotech firm (Crucell) that makes and develops flu vaccines. Merck which already makes vaccines for shingles and other diseases, struck a deal to distribute flu shots made by Australian CSL," ABC News reported on October 14, 2009

The vaccine market is booming. Its an enormous growth area for pharmaceuticals at a time when other areas are not doing so well, Bruce Carlson, a spokesperson for the market research firm Kalorama, told ABC News.

"The vaccine market is booming. It's an enormous growth area for pharmaceuticals at a time when other areas are not doing so well," Bruce Carlson, a spokesperson for the market research firm Kalorama, told ABC News.

The most recent estimates have GlaxoSmithKline reaping some $4.8 billion from the pandemic, between its Pandemrix vaccine, its Relenza antiviral drug, and other products such as antiviral face masks and flu diagnostics, Fierce Pharma reported on October 9, 2009.

The most recent estimates have GlaxoSmithKline "reaping some $4.8 billion from the pandemic, between its Pandemrix vaccine, its Relenza antiviral drug, and other products such as antiviral face masks and flu diagnostics," Fierce Pharma reported on October 9, 2009.

Full Story

Leave a Reply